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TNF-related apoptosis-inducing ligand (TRAIL, also known as Apo-2L) is a promising novel anticancer agent that selectively induces
apoptosis in tumour cells and the activity of which can be enhanced by combined treatment with chemo- or radiotherapy. For
therapeutic purposes, the use of full-length TRAIL may be favourable to recombinant TRAIL based on its increased tumour cell killing
potential, and the delivery of TRAIL at the tumour site by adenovirus vectors may provide an approach to overcome the short half-
life of recombinant TRAIL and hepatocyte toxicity in vivo. Here, we constructed an adenoviral vector expressing full-length TRAIL
(AdTRAIL) and studied the potential of chemo- and radiotherapy in enhancing AdTRAIL-induced apoptosis in non-small cell lung
cancer (NSCLC) H460 cells and normal cells and, in addition, investigated the mechanism of AdTRAIL-induced apoptosis. AdTRAIL
effectively killed H460 cells, which we previously showed to have a deficiency in mitochondria-dependent apoptosis by downstream
activation of caspase-8 rather than caspase-9. Further analyses revealed that AdTRAIL induces death receptor- and mitochondria-
dependent apoptosis that could be partially suppressed by Bcl2 overexpression. Combined treatment with doxorubicin (DOX),
cisplatin (CDDP), paclitaxel (PTX) and radiation strongly enhanced AdTRAIL-induced cytotoxicity in a synergistic way. Synergy was
accompanied by the cleavage of Bid and an increase in caspase-8 processing that was abolished by Bcl2 overexpression, indicating
that the Bid-mitochondrial amplification loop is functional in H460 cells. Moreover, combination treatment did not alter the tumour
selectivity of AdTRAIL since normal human fibroblasts (NHFs) remained resistant under these conditions. These findings further
indicate that the combined use of chemo/radiotherapy and adenovirus-produced full-length TRAIL may provide a valuable treatment
option for NSCLC.
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The treatment of advanced cancer, including non-small-cell lung
cancer (NSCLC), is often hampered by the intrinsic or developing
resistance against the anticancer drugs used (De Vita et al, 2001).
In this context, deregulated apoptosis in cancer can contribute to
drug resistance since the apoptosis-inducing ability of therapeutic
agents is at least partially responsible for drug efficacy. Efforts to
circumvent drug resistance include the combined use of different
drugs with different mechanisms of action to enhance the overall
antitumour effect, which for example can be based on the
activation of distinct or overlapping apoptotic pathways that in a
cooperative manner can trigger apoptosis more effectively.
TNF-related apoptosis-inducing ligand (TRAIL, also known as
Apo-2L) represents a novel promising anticancer agent whose
activity is solely dependent on its ability to induce apoptosis in
tumour cells (Ferreira et al, 2002; MacFarlane, 2003). Unlike other
members of the TNF super family (TNF and FasL), TRAIL acts as a
specific antitumour agent without harming normal cells (Huang
et al, 2002; Lin et al, 2002a,b). TNF-related apoptosis-inducing
ligand is a type-II transmembrane protein and shows the highest
homology to FasL. The extracellular domain of TRAIL forms a
soluble molecule upon cleavage (Wiley et al, 1995; Pitti et al, 1996).
Both soluble and full-length TRAIL bind to their cognate cell
surface receptors in the target cell to engage the apoptotic pathway
(Ashkinazi et al, 1999) although the two TRAIL variants have been
reported to possess different apoptosis-inducing capacities in
cancer cells suggesting currently unresolved differences in their
mechanism of action (Voelkel-Johnson et al, 2002; Seol et al, 2003).
Of the five TRAIL receptors identified so far, TRAIL-R1 (DR4),
TRAIL-R2 (DR5/TRICK/KILLER) and TRAIL-R4 (DcR1/
TRUNDD) encode classical type-I transmembrane proteins (Pan
et al, 1997a,b). The TRAIL-R1 and -R2, which signal for apoptosis,
have a complete cytoplasmic death domain (DD) while R3 and R4
act as decoy receptors having either no or a truncated cytoplasmic
domain, respectively.
In animal experiments, TRAIL did not cause systemic toxicity
(Kagawa et al, 2001). It was however reported that recombinant
his-tagged TRAIL could cause toxicity to human, but not murine -
or non-human primate hepatocytes in vitro (Jo et al, 2000), which
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shas been assigned to conformational changes in TRAIL structure
caused by the histidine tag (Lawrence et al, 2001). Apart from the
issue of hepatotoxicity, soluble TRAIL has demonstrated a potent
antitumour activity against a wide range of tumours both in vitro
and in vivo (Pitti et al, 1996; Nimmanapalli et al, 2001; Rohn et al,
2001; Naka et al, 2002).
The applicability of soluble TRAIL in cancer therapy, however,
is limited by its short half-life in vivo (Kelley et al, 2001) that may
be overcome by the production of TRAIL at the tumour site by for
example a nonreplicating adenoviral vector, which will also reduce
the risk of hepatotoxicity (see also Griffith et al, 2000; Lin et al,
2002a).
The mechanism of TRAIL-induced apoptosis has been studied
and the majority of cells can be classified as type I, that is, TRAIL-
induced apoptosis is solely mediated by the death receptor
pathway (Walczak et al, 2000). In this case, the binding of TRAIL
to its death receptors triggers the aggregation of the death-
inducing signal complex (DISC) with subsequent caspase-8
activation and the activation of executioner caspases and
consequently irreversible apoptosis. On the other hand, type-II
cells, including several colon carcinoma, neuroblastoma and
NSCLC cell lines, are characterized by a strong involvement of
the mitochondrial pathway via the caspase-8-dependent activation
of the proapoptotic Bcl2 family member Bid, also known as the
amplification loop (Sun et al, 2001; Fulda et al, 2002; Ozoren and
El-Deiry, 2002). In addition, the combined treatment with different
chemotherapeutic agents or ionising radiation is known to
enhance the antitumour activity of soluble TRAIL in additive or
synergistic manners, both in vitro and in vivo models, and has
been related to the increased activation of the mitochondrial
pathway but also to the enhanced expression of TRAIL receptors
(Gibson et al, 2000; Held and Schulze-Osthoff, 2001; Mitsiades et al,
2001; Xu et al, 2003).
In this study, we examined the apoptosis-inducing effect of a
constructed adenoviral vector expressing full-length TRAIL in the
NSCLC cell line NCI-H460 and in normal cells when applied alone
or in combination with different types of chemotherapeutic agents
and radiation. It should be noted that NSCLC cells have a
deficiency in the mitochondrial apoptotic pathway in that caspase-
8 is activated rather than caspase-9 caused by a yet unknown
disturbance in apoptosome functioning (Ferreira et al, 2000).
Owing to this and the relative lack of knowledge on the mechanism
underlying full-length TRAIL-induced apoptosis, we also ad-
dressed the functioning of the mitochondria amplification loop
in this context.
Our findings indicate that adenoviral expression of full-length
TRAIL in combination with chemo/radiotherapy may provide an
effective and selective strategy for the treatment of NSCLC.
MATERIALS AND METHODS
Cell culture and treatment
Human non-small-cell lung adenocarcinoma (NSCLC) NCI-H460
cells and Bcl2 stable overexpressing derivatives (H460Bcl2,
described earlier (Ferreira et al, 2000) were cultured in RPMI
1640 medium (Invitrogen, Breda, The Netherlands) and normal
human fibroblasts (NHF) in Nutrient mixture F10 (Invitrogen).
Both media were supplemented with 10% heat-inactivated foetal
calf serum (Invitrogen, Breda, The Netherlands), 50IUml
 1
penicillin, 50mg streptomycin and 1mgml
 1 puromycin (only for
H460Bcl2 cells) and cells were grown at 371C in a humidified air
with 5% CO2. Cell lines were routinely tested for the absence of
mycoplasma infection before use. The expression of Bcl2 protein
was confirmed by immunohistochemistry before starting the
experiments (data not shown). For optimal adenoviral infection,
near-confluent cell cultures were used throughout the study. Cells
were treated with doxorubicin (DOX, purchased from Pharmacia
Upjohn BV (Woerden, The Netherlands), paclitaxel (PTX,
purchased from Sigma, Zwijndrecht, The Netherlands), cisplatin
(CDDP, purchased from Pharma Chemie BV, Harlem, The
Netherlands) or 6Gy ionising radiation (80-kV orthovolt X-ray
source (Pantak Therapax SXT 150)). For caspase inhibition, the
synthetic inhibitor zVAD-fmk (Enzyme System Products, Liver-
more, CA, USA) was used.
Adenovirus construction
The TRAIL open reading frame (ORF), kindly provided by Dr H
Yagita, Juntendo University School of Medicine, Japan, was cloned
under the control of the immediate early cytomegalovirus (CMV)
promoter in the pShuttle plasmid and subsequently recombined
with the pAdeasy plasmid for the production of replication
incompetent AdTRAIL The adenovirus vectors were propagated in
293 cells and purified by CsCl density gradient. The viral
preparations were dialysed and stored at  801C until use.
The titer of AdTRAIL stock, as determined by the limiting
dilution assay, was 3.5 10
9 plaque forming unit (pfu)/ml and the
viral particle to pfu ratio measured at OD260 was less than 60. The
adenovirus stocks were free of replication competent adenovirus
(RCA) as tested by PCR using primers flanking the AdE1A region
(Abou El Hassan et al, 2003). The adenovirus expressing green
fluorescence protein (GFP) was used as a control and was
described earlier (Van Beusechem et al, 2000).
Infection and cytotoxicity measurement
H460, H460Bcl2 and NHF cultured in 96-well plates were incubated
with different multiplicity of infection, that is, virus to cell ratio
(MOI) of AdTRAIL as indicated in growth medium (50ml/well) at
371C. At 2h postinfection, another volume of virus-free growth
medium was added. Cytotoxicity of AdTRAIL alone or combined
with other treatments was determined by MTT assays as described
previously (Abou El Hassan et al, 2003a).
The percentage survival (taking the blank as 100% survival) was
plotted as a function of MOI or drugs concentration. The LC50
values of each drug with (out) preinfection with AdTRAIL – that is,
the concentration of drug required to kill 50% of the cultured cells
– were determined and the derived sensitisation factors were
calculated as the ratio of the LC50 of drug alone/LC50 of drug with
AdTRAIL infection.
Western blotting
Treated cells were lysed 24, 48 and 72h postinfection with RIPA
buffer (50mM Tris-HCl, 150mM NaCl, 0.1%. SDS, 0.5% sodium
deoxycholate (DOC, Fluka Biochemika, Buchs, Switzerland) and 1%
nonidet P40 (NP40, Fluka Biochemika)). The cellular lysates were
immediately stored at  801C. Protein (50mg) of each sample
(determined by Biorad total protein assay (Bio-Rad Laboratories
BV, Veenendaal, The Netherlands) were separated on a 12.5% SDS–
PAGE. Thereafter, proteins were blotted on Immobilon membrane
(Millipore BV, Etten-Leur, The Netherlands) and subsequently
incubated in blocking solution containing 5% nonfat milk in TBST
(0.2% Tween 20, 150mM NaCl and 10mM Tris-HCl, pH 8).
The following primary antibodies were used: rabbit polyclonal
anti-human TRAIL (dilution 1:1000; PeproTechLTD, London,
UK), rabbit polyclonal anti PARP (dilution 1:2000; Roche, Basel,
Switzerland), anti-caspase 8mAb (dilution 1:2000; Immunotech,
Prague, Czech Rep), rabbit polyclonal anti-Bid (dilution 1:2000;
Roche) and anti-b-actin mAb (dilution 1:7500; Sigma, St Louis,
MO, USA). After incubation for 1–2h with the primary antibody
and washing in TBST, the blots were incubated with peroxidase-
conjugated goat anti-rabbit/rabbit anti-mouse 2
ry antibody
(DAKO, Glostrup, Denmark) (1:1250 dilution). For chemolumi-
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snescence detection, blots were immersed in Lumi-light plus mix
(Roche) and exposed to hyperfilm (Amersham Pharmacia UK Ltd.,
Bukinghamshire, UK).
Immunohistochemistry
H460 and NHF cells cultured in 96-well plate were infected with
AdTRAIL (MOI 100). At 3 days postinfection, cells were fixed with
chilled methanol:acetone mix (1:1, vv
 1). TNF-related apoptosis-
inducing ligand expression was monitored with rabbit polyclonal
anti-human TRAIL antibody (dilution 1:200; PeproTechLTD), for
1h at 371C. After washing with PBS, cells were incubated with
peroxidase-conjugated goat anti-rabbit secondary antibody. The
stained cells were visualised using AEC substrate chromogen
(DAKO).
RESULTS
Construction and characterisation of AdTRAIL
An adenoviral vector expressing full-length TRAIL was con-
structed as described in the Materials and Methods section.
Figure 1A shows the expression of TRAIL in H460 cells followed up
to 3 days postinfection with different MOIs of AdTRAIL. The
cellular expression of TRAIL was MOI dependent and reached its
maximal level at 1 day postinfection. Further increases in TRAIL
expression were likely limited by the toxic effect of TRAIL on the
infected producer cells. The MOI-dependent killing of H460 cells
by AdTRAIL was confirmed 3 days postinfection by MTT assays as
shown in Figure 1B.
To demonstrate apoptosis activation triggered by adenovirus-
produced TRAIL, we tested whether the broad caspase inhibitor
zVAD-fmk would protect against AdTRAIL toxicity. A complete
abrogation of AdTRAIL-induced apoptosis was observed by
cotreating H460 cells with different concentrations of zVAD-fmk
at 3 days posttreatment (Figure 2A), indicating the sole involve-
ment of caspases in mediating AdTRAIL-induced apoptosis. To
further characterise caspase dependency of AdTRAIL-induced
apoptosis, the cleavage of procaspase-8 and PARP was determined in H460 cells 3 days postinfection with AdTRAIL by Western
blotting. AdTRAIL specifically induced procaspase-8 and PARP
cleavage as indicated in Figure 2B, when compared to uninfected
or AdGFP-infected cells.
Combination treatment of AdTRAIL with
chemo(radio)therapy
Figure 3 shows the combined effect of different types of
chemotherapeutic drugs, DOX, PTX, CDDP or 6Gy irradiation
with AdTRAIL (MOI 10) on the viability of H460 cells at 3 days
after treatment. Under these conditions, AdTRAIL caused
moderate cell killing in H460 cells with a viability of 78.676.9%
of control noninfected cells. Doxorubicin, PTX or CDDP alone
induced a concentration-dependent cell kill of H460 cells with LC50
values of 1.5, 0.3 and 15mM, respectively (see also Table 1).
Interestingly, the combined treatment with subtoxic concentra-
tions of DOX, PTX or CDDP already sensitised H460 cells to
AdTRAIL-induced apoptosis (Pp0.05, Figure 3). Accordingly, the
LC50 values of DOX, PTX and CDDP were reduced 100-, 150- and
10-fold, respectively (Table 1). Likewise, the use of 6Gy ionising
radiation, which did not result in cytotoxicity in H460 cells,
augmented the apoptotic effect of AdTRAIL in H460 cells at 3 days
postinfection.
In order to study whether the mitochondria amplification loop
mediates the observed synergistic effects in the mitochondria/
caspase-9 pathway impaired H460 cells, Bcl2-overexpressing
cells (H460Bcl2) were treated with AdTRAIL alone or combined
with chemotherapy or irradiation. The overexpression of Bcl2
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Figure 1 TNF-related apoptosis-inducing ligand expression and survival
of Ad-TRAIL-infected H460 cells. Cells were infected with different MOIs
of AdTRAIL, and TRAIL expression was determined by Western blotting at
1, 2 and 3 days postinfection (A). Survival of infected cells was determined
by MTT assays at 3 days postinfection (B).
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Figure 2 AdTRAIL induces caspase-dependent apoptosis in H460 cells.
H460 cells were treated with AdTRAIL (MOI 10) in the presence or
absence of zVAD-fmk, and after 3 days postinfection cell viability was
determined (A). Values are the mean (n¼3)7s.d., and P-values were
determined by the Student’s t-test. Western blot indicating the cleavage of
procaspase-8 and PARP (B). Arrows indicate the cleaved products of
PARP.
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ssignificantly protected H460 cells against AdTRAIL-induced
apoptosis (compare Figures 3 and 4).
In addition, H460Bcl2 cells could not be sensitised to AdTRAIL
by DOX, CDDP and 6Gy-irradiation, whereas the sensitising effect
of PTX was strongly reduced but not completely abolished (P40.1,
Figure 4 and Table 1). As control, the combined treatment with
chemo (radio)therapy did not sensitise H460 cells infected with the
AdGFP (MOI 100) control virus (data not shown).
Bcl2 overexpression prevents caspase-8 activation and Bid
cleavage
To further examine the role of Bcl2 in preventing the potentiating
effect of chemotherapy and ionising radiation to AdTRAIL-
induced apoptosis, we studied the cleavage of procaspase-8 and
Bid in H460 and H460Bcl2 cells after infection with AdTRAIL
(MOI 10) alone or in combination with 15nM DOX or PTX, 15mM
CDDP or 6Gy irradiation 3 days postinfection. Figure 5 shows that
control adenovirus infection (AdGFP) did not induce caspase-8
activation or Bid cleavage in H460 and H460Bcl2 cells as indicated
by the constant levels of the nonprocessed forms. AdTRAIL
infection induced caspase-8 and Bid cleavage, which was enhanced
upon combined treatment with chemo (radio) therapy in H460
cells. The overexpression of Bcl2 almost completely prevented the
cleavage of Bid in cells treated with AdTRAIL alone and when
combined with chemo (radio) therapy, and also reduced
procaspase-8 cleavage. This indicates that the lack of chemo/
radiation-dependent sensitisation of H460Bcl2 cells to AdTRAIL is
related to the Bcl2-dependent prevention of the enhanced
processing of procaspase-8 and Bid.
Effect of AdTRAIL combination treatment on normal cells
To study the possibility that under conditions of chemotherapy
enhanced Ad TRAIL-induced H460 cell killing the sensitivity to
normal cells could also be altered, we treated NHF cells in the same
way and determined cytotoxicity. For this purpose, first the
infection efficiency of NHF was examined. Figure 6A shows a
considerable level of AdGFP infection at MOI 100 in NHF cells of
approximately 20%, whereas H460 cells demonstrated an infection
efficiency of around 70%.
Infection with AdTRAIL eradicated most of the H460 cells but
left the NHF intact as indicated by the few remaining cells that
were either positive or negative for TRAIL expression in H460 cells
as determined by immunohistochemistry (Figure 6B). Subse-
quently, the effect of combined chemotherapy at different
concentrations with AdTRAIL on NHF cells was examined
(Figure 7). Each of the drugs alone exerted a concentration-
dependent cytotoxicity on NHF cells 2 days post-treatment.
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Figure 3 Cytotoxic effect of AdTRAIL (MOI 10) alone or in combination with different concentrations of DOX, PTX, CDDP or 6Gy irradiation in H460
cells at 3 days postinfection. Values are the mean (n¼3)7s.d. The P-values were calculated by comparing the slopes of the multiple regression of ln
(viability2) of H460 cells treated with AdTRAIL alone or combined with DOX, PTX or CDDP vs ln (drug conc.
2) by Student’s t-test. For the irradiated
groups, the P-value was calculated by comparing the viability of cells treated with AdTRAIL alone or in combination with 6Gy irradiation using Student’s test.
Table 1 AdTRAIL-induced sensitisation of H460, H460Bcl2 and NHF
cells to DOX, PTX or CDDP 2 days after treatment
LC50 (mM)
DOX PTX CDDP
  +AdTRAIL   +AdTRAIL   +AdTRAIL
H460 1.5 0.015 0.3 0.002 15 1.5
SF
a 100 150 10
H460Bcl2 0.5 0.25 0.1 0.005 15 15
SF
a 22 01
NHF 3 3 90 85 28 35
SF
a 1 1.1 0.8
aSensitisation factor. DOX¼doxorubicin; CDDP¼cisplatin; PTX¼paclitaxel;
LC50¼the concentration of drug required to kill 50% of the cultured cells;
NHFs¼normal human fibroblasts.
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sNormal human fibroblasts were relatively refractory to the damage
induced by the chemotherapeutic agents (especially to PTX) when
compared to H460 cells (see Table 1). The cotreatment of NHF
with different concentrations of DOX, PTX or CDDP 24h
postinfection with AdTRAIL did not result in extra cytotoxicity
either compared to AdTRAIL alone or chemotherapy alone.
Instead, perhaps even an increase in viability after AdTRAIL
infection could be appreciated (Figure 7). These data show that
adenovirus-expressed TRAIL combined with chemotherapy does
not alter the sensitivity of normal cells.
DISCUSSION
Adenovirus-mediated production of the promising biological
anticancer agent TRAIL is a form of proapoptotic gene therapy
that has gained considerable attention recently (Griffith et al, 2000;
Routes et al, 2000; Lin et al, 2002b). The main reasons for this are
the intrinsic tumour-selective activity of TRAIL in a broad range of
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Figure 4 Cytotoxic effect of AdTRAIL (MOI 10) alone or in combination with different concentrations of DOX, PTX, CDDP OR 6Gy irradiation in
H460Bcl2 cells at 3 days postinfection. Values are the mean (n¼3)7s.d. The P-value was calculated by comparing the slopes of the multiple regression of ln
(viability2) of H460Bcl2 cells treated with AdTRAIL alone or combined with DOX, PTX or CDDP vs ln (drug conc.2) by Student’s t test. For the irradiated
groups, the P-value was calculated by comparing the viability of cells treated with AdTRAIL alone or in combination with 6Gy irradiation using Student’s test.
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Figure 5 Bid and procaspase-8 cleavage in H460 and H460Bcl2 cells 3
days postinfection with AdTRAIL (MOI 10) with (out) 15nM of DOX or
PTX, 15mM CDDP or 6Gy irradiation.
H460 NHF 
×40
×20
A
B
Figure 6 AdGFP and AdTRAIL infection of H460 and NHF cells. Cells
were infected at MOI 100, and after 3 days, GFP expression (A) or TRAIL
expression (B) was determined.
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scancer cells that complements the rather nonselective delivery of
viral vectors to tumours and normal tissues, the observed
bystander effect of TRAIL resulting in the killing of cells
surrounding the infected cells (Kagawa et al, 2001), and the
notion that virally produced TRAIL may overcome problems
observed with the use of recombinant soluble TRAIL regarding
protein instability and resistance (Kelley et al, 2001; Voelkel-
Johnson et al, 2002; Seol et al, 2003).
Full-length TRAIL has recently been reported to kill tumour
cells that are resistant to soluble TRAIL, suggesting a greater
therapeutic potential of this form and indicating the existence of
yet not understood mechanistic differences between the two
TRAIL variants (Voelkel-Johnson et al, 2002; Seol et al, 2003).
The tumour-selective properties of full-length TRAIL alone or in
combination with chemo- and radiation treatment thus far have
been mainly investigated and confirmed for recombinant TRAIL,
and its mechanism of action has been left unexplored.
In the present study, we generated an adenoviral vector
expressing full-length TRAIL to explore its possible use for the
treatment of NSCLC. We used the NSCLC cell line H460 as a
representative cell line that has been well characterised and in
which we found a defect in mitochondria-dependent caspase-9
activation upon treatment with DNA-damaging chemotherapeutic
agents that may provide an explanation for chemoresistance of
NSCLC in the clinic (Ferreira et al, 2000).
AdTRAIL efficiently killed H460 cells in a MOI-dependent
manner, which could be inhibited by the broad-caspase-inhibitor
zVAD-fmk as an indication of the activation of caspase-dependent
apoptosis. AdTRAIL-induced apoptosis in H460 was associated
with caspase-8 activation and PARP cleavage. Subtoxic doses of
DOX, PTX, CDDP or ionising radiation sensitised H460 cells to
AdTRAIL-induced apoptosis that we found to be a result of
augmented processing of procaspase-8 and Bid, indicating that
both TRAIL and chemo (radio) therapy-induced apoptotic signals
converge at the mitochondrial apoptotic pathway. The most likely
explanation for this is that both chemotherapeutic agents and
irradiation trigger damage-induced signals that lead to the
activation of proapoptotic Bcl2 family members, such as Bax and
Bak (Cartron et al, 2003; Kim et al, 2003), and subsequent
mitochondria destabilisation that as we reported previously results
in the unusual activation of caspase-8 in NSCLC H460 cells by an
as yet unresolved mitochondria-dependent mechanism (Ferreira
et al, 2000). Consequently, Bid cleavage is enhanced and as a result
the tBid-dependent amplification loop.
Confirmation for this notion is provided by our finding that the
stable overexpression of Bcl2 in H460 cells completely counter-
acted the enhancing effect of chemo (radio) therapy, except for
PTX. Paclitaxel-induced toxicity was significantly reduced by Bcl2
overexpression, but not completely abrogated as found for the
other treatments. This may be related to our previous finding that
PTX in contrast to, for example CDDP, induces cell death in H460
cells that is only partially triggered through the mitochondrial
pathway and mainly depends on the activation of a caspase-
independent pathway (Huisman et al, 2002). The found impor-
tance of the tBid-mitochondria amplification loop in mediating
AdTRAIL-induced apoptosis in H460 cells classifies them as type-
II cells. This observation is in line with a previous report by Sun
et al (2001), who showed that Bcl2 overexpression inhibits soluble
TRAIL-induced apoptosis in NSCLC cells; however, instead of their
suggestion that Bcl2 acts by preventing caspase-7 activation, we
find that Bcl2 suppresses procaspase-8 cleavage that as mentioned
above we have found to occur in a mitochondria-controlled
manner in NSCLC cells (Ferreira et al, 2000).
The notion was also tested whether the use of the full-length
TRAIL-encoding virus together with chemotherapy may affect the
tumour selectivity of the treatment and result in toxic side effects
on normal tissue. We did not observe such a change in cytotoxicity
in NHF and rather observed a not understood small increase in
viability after AdTRAIL infection.
In conclusion, we showed that the production of full-length
TRAIL by an adenoviral vector effectively kills NSCLC H460 cells
that can be enhanced by combined treatment with the chemother-
apeutic agents CDDP, DOX and PTX and by radiation. The
synergistic effects are dependent on the enhanced activation of the
mitochondria apoptotic pathway that remains functional in the
mitochondria/caspase-9 route-deficient H460 cells. Combination
treatment of AdTRAIL and chemo/radiotherapy was not toxic for
normal cells indicating that adenovirus-directed expression of full-
length TRAIL might provide an attractive strategy for treating
NSCLC.
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Figure 7 Chemotherapy in combination with AdTRAIL does not alter
the sensitivity of NHF. The cytotoxic effect of AdTRAIL (MOI 100) with
(out) different concentrations of DOX, PTX and CDDP was determined at
3 days postinfection. Values are the mean (n¼3)7s.d. The P-value was
calculated by comparing the slopes of the multiple regression of NHF cells
ln (viability2) treated with AdTRAIL alone or combined with DOX, PTX or
CDDDP vs. ln (drug conc.
2) by Student’s t-test.
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